Related Experiment Video
Updated: Jul 3, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Better pharmacotherapy for schizophrenia: what does the future hold?
Michael A Webber1, Stephen R Marder
1Semel Institute for Neuroscience at UCLA, Mental Illness Research, Education, and Clinical Center, VA West Los Angeles Health Care Center, MIRECC 210A, 11301 Wilshire Boulevard, Los Angeles, CA 90073-1003, USA.
Current Psychiatry Reports
|July 17, 2008
Summary
Current antipsychotics improve psychosis in schizophrenia but not functional outcomes. Novel drug development targeting negative symptoms and cognitive impairment is crucial for functional recovery in schizophrenia patients.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Antipsychotic medications have advanced over 50 years, yet functional outcomes for schizophrenia patients remain poor.
- Current antipsychotics are effective for psychosis but do not address negative symptoms or cognitive deficits, which significantly impact daily functioning.
- Treatment-refractory psychosis and persistent negative/cognitive symptoms hinder functional recovery in many individuals.
Purpose of the Study:
- To review novel pharmacologic strategies for schizophrenia that target specific domains of the illness.
- To explore therapeutic approaches beyond D2 receptor antagonism to address unmet needs in schizophrenia treatment.
- To shift the focus of pharmacotherapy from psychosis remission to achieving functional recovery.
Main Methods:
- Review of current literature on novel pharmacologic targets for schizophrenia.
- Analysis of emerging drug development pipelines for negative symptoms and cognitive impairment.
- Discussion of the pathophysiological basis for distinct symptom domains in schizophrenia.
Main Results:
- Existing antipsychotics primarily target psychosis via D2 receptors, with limited efficacy on other symptom domains.
- Novel therapeutic strategies are being investigated to specifically address negative symptoms and cognitive dysfunction.
- Understanding the distinct pathophysiologies of schizophrenia domains is key to developing targeted treatments.
Conclusions:
- Future pharmacotherapy for schizophrenia must adopt a multi-domain approach to improve functional outcomes.
- Developing drugs that target negative symptoms and cognitive impairment is essential for patient functional recovery.
- Moving beyond D2 receptor blockade is necessary to achieve comprehensive treatment advancements in schizophrenia.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...